BMMP |
Catalog No.GC78874
One-Click Copy Product Info
|
BMMP is an anti- HIV-1 agent and hnRNP M modulator.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 748785-70-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, BMMP (20 μM; 2 d) does not reduce the viability of 293T or M8166 cells[1]. BMMP (20 μM; 3 d) inhibits full-cycle HIV-1 replication across 293T and M8166 cells to 30% of control levels[1]. BMMP (20 μM) does not affect the release of HIV-1 virions from 293T cells[1]. BMMP (20 μM; 1 d) does not significantly alter the infectivity of HIV-1 virions produced by 293T cells[1]. BMMP (20 μM; 1 d) potently inhibits early-phase HIV-1 infectivity in M8166 cells to less than 10% of control levels[1]. BMMP (20 μM; 2 d) does not affect HIV-1 reverse transcription but suppresses nuclear localization and integration of viral DNA in 293T cells, reducing 2-LTR DNA to 60% and Alu-LTR DNA to 46% of control levels[1]. BMMP (20 μM; 1 d) destabilizes HIV-1 CA protein in infected HeLa cells[1]. BMMP (20 μM; 1 d) does not change the nuclear localization of hnRNP M but reduces HIV-1 CA protein levels in infected HeLa cells[1]. BMMP (20 μM; 1 d) inhibits early-phase HIV-1 infectivity in both control and hnRNP M-knockdown HeLa cells, indicating hnRNP M is not involved in BMMP's anti-HIV activity[1]. BMMP (0.1-100 μM; 2 d) at 0.1-50 μM does not reduce A549 cell viability, while 100 μM BMMP shows mild toxicity[1]. BMMP (0.1-100 μM; 24 h total incubation with TGF-β stimulation) inhibits TGF-β-induced migration of A549 cells in a concentration-dependent manner, with near-complete inhibition at 20 μM[1]. BMMP (20 μM; 1 h, 3 h, 6 h, or 1 d incubation with TGF-β stimulation) slightly reduces vimentin mRNA levels but does not inhibit TGF-β-induced EMT marker changes in A549 cells[1]. BMMP (20 μM; 1 d incubation with TGF-β stimulation) reduces TGF-β-induced increases in CD44s, CD44v8, and CD44v10 mRNA levels in A549 cells[1]. BMMP (20 μM; 1 d incubation with TGF-β stimulation) reduces TGF-β-induced CD44 mRNA expression in A549 cells via hnRNP M, as the effect is abolished in hnRNP M-knockdown cells[1]. BMMP (20 μM; up to 100 hours) inhibits replication of HIV-1 NL4-3 strain in human T-lymphoblastoid M8166 cells[2]. BMMP does not directly interact with HIV-1 Pr55Gag or CA protein in a cell-free surface plasmon resonance assay[2].
References:
[1]. Kamo M, et al. Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M. Bioorg Chem. 2021;107:104627.
[2]. Kamo M, et al. Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study. Bioorg Med Chem Lett. 2016;26(1):43-45.
| Cas No. | 748785-70-8 | SDF | |
| Formula | C13H11N3S2 | M.Wt | 273.38 |
| Solubility | DMSO: 100 mg/mL (365.79 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6579 mL | 18.2896 mL | 36.5791 mL |
| 5 mM | 731.6 μL | 3.6579 mL | 7.3158 mL |
| 10 mM | 365.8 μL | 1.829 mL | 3.6579 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)